I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AACR 2021

Coming soon
03:30 PM
Duration 15mins Virtual
IMbrave150: efficacy and safety in high-risk patients (pts) receiving atezolizumab▼ (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
RS Finn, S Qin, M Ikeda, P Galle, M Ducreux, TY Kim, HY Lim, M Kudo, V Breder, P Merle, A Kaseb, D Li, Y-H Feng, W Verret, H Shao, A Nicholas, L Li, AX Zhu, AL Cheng
01:30 PM
Duration 10mins Virtual
Atezolizumab▼ (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): updated overall survival (OS) from the randomized Phase III study IMvigor130
Matt Galsky, José Ángel Arranz Arija, Enrique Grande, Maria De Santis, Ian D Davis, Eiji Kikuchi, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente Vazquez, Jian-Ri Li, Peter O'Donnell, Xiaodong Shen, Chooi Lee, Almut Mecke, Sanjeev Mariathasan, Aristotelis Bamias
Duration 10mins Virtual
Updated OS analysis of atezolizumab▼ (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130
Ian D Davis, Matthew Galsky, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Javier Puente Vazquez, Jian-Ri Li, José Ángel Arranz Arija, Aristotelis Bamias, Enrique Grande, Eiji Kikuchi, Almut Mecke, Sanjeev Mariathasan, Xiaodong Shen, Xinhui Huang, Maria De Santis
03:30 PM
Duration 10mins Virtual
Efficacy of atezolizumab▼ in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort
Hainsworth J, Friedman C, Kurzrock R, Burris H, Spigel DR, Sweeney CJ, Meric-Bernstam F, Wang Y, Levy J, Shames D, Schulze K, Patel A, Swanton C